- Citations, last 5 years
- 83
- Works, last 5 years
- 11
- h-index
- 32
- Scientists listed
- 0
- Grants since 2016
- 17
Grants received
2023 · grant
Cassava Republic Press (2023)
Cassava Sciences (United States) · funded by Open Society Foundations
2021–2022 · research · R01
Food Effect study and drug supply scale-up for PTI-125
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2020–2021 · research · R44
Open-label extension of a 3-month blinded clinical trial of PTI-125
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Increasing size of Phase 2b clinical trial to 60 patients
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2018 · research · R44
Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2018 · research · R44
Extending clinical trial in AD patients from 1 to 3 months
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2017–2018 · research · R42
Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2017–2018 · research · R44
IND, FIH study and 3-month tox for PTI-125, a novel therapeutic for Alzheimer's disease
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch
Shawn Kucera · Cassava Sciences (United States) · funded by National Institutes of Health
2017–2018 · research · R44
Additional bioanalytical, dose analysis and DSMB costs for PTI-125 development
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2017–2022 · research · R44
Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch
Shawn Kucera · Cassava Sciences (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Solid oral dosage form and chronic tox for PTI-125
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Additional costs related to formulation, chronic tox and general development of PTI-125
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health
2017 · research · R44
IND, FIH study and 3-month tox for PTI-125, a novel therapeutic for Alzheimer's disease
Lindsay H Burns · Cassava Sciences (United States) · funded by National Institutes of Health